13F
← All fund report cards

GRS Advisors, LLC

13F equity value
$1.0B
Positions
32
Top 10 concentration
54.3%
Quarters / total new picks
32 / 216
13F equity value over time
$0M$557M$1B2017201820192020202120222023202420252026

"13F equity value" = market value of this filer's US-listed long equity positions only. It excludes cash, bonds, non-US and short positions, so it understates a fund's true assets under management — often by a lot.

Not significant Verdict

13F holdings are disclosed ~45 days after quarter-end, and they never reveal when within the quarter a fund actually bought. So any 13F-based summary is structurally late and blurred — this applies to every fund, including this one.

We backtested copying it anyway. Buying this fund's new positions the day each filing went public, over 32 quarters, returned +1.2% per quarter — versus +2.7% per quarter from simply owning every 13F stock. It beat that baseline in only 37.5% of quarters (excess t = -1.45, not statistically significant). Its filings tell you what it bought — not what you should buy.

Avg 2Q excess
-2.4%
t-stat
-1.45
Quarterly win rate
38%
Annualized excess
-6.0%
$1 → follow vs universe
$1.33 vs $2.09
Cumulative return: $1 invested in new picks vs universe
1.00 20180331: universe 1.04120180630: universe 0.95920180930: universe 1.00320181231: universe 0.99220190331: universe 0.97520190630: universe 1.04820190930: universe 1.12720191231: universe 0.90920200331: universe 1.09620200630: universe 1.21120200930: universe 1.48520201231: universe 1.55320210331: universe 1.56620210630: universe 1.69220210930: universe 1.51920211231: universe 1.29220220331: universe 1.38720220630: universe 1.28520220930: universe 1.38120221231: universe 1.28220230331: universe 1.35120230630: universe 1.30320230930: universe 1.47920231231: universe 1.54520240331: universe 1.58020240630: universe 1.72320240930: universe 1.70820241231: universe 1.59420250331: universe 1.73820250630: universe 1.79320250930: universe 2.01620251231: universe 2.085 20180331: follow 1.10620180630: follow 0.99720180930: follow 1.06420181231: follow 1.02320190331: follow 1.03920190630: follow 1.06520190930: follow 1.16920191231: follow 0.95620200331: follow 1.08620200630: follow 1.13120200930: follow 1.29320201231: follow 1.34120210331: follow 1.36920210630: follow 1.45820210930: follow 1.43120211231: follow 1.27420220331: follow 1.31520220630: follow 1.20420220930: follow 1.27720221231: follow 1.12420230331: follow 1.18920230630: follow 1.18520230930: follow 1.24420231231: follow 1.31020240331: follow 1.45320240630: follow 1.51620240930: follow 1.43020241231: follow 1.32320250331: follow 1.30720250630: follow 1.30520250930: follow 1.41320251231: follow 1.333 0.84 1.54 2.25 20182019202020212022202320242025 Follow Universe

Quarterly compounding, invested quarters only · entry 47 days after quarter-end (when 13F data becomes public)

Listed as facts. See the verdict above before treating this as signal.

Top 20 holdings of 32 · 2026 Q1

Ticker Value Weight QoQ
PLD $82M
8.1%
NEW
FRT $73M
7.2%
ADD
WH $61M
6.0%
TRIM
VTR $51M
5.1%
ADD
CDP $50M
5.0%
ADD
BNL $49M
4.8%
NEW
CTRE $48M
4.8%
TRIM
AHR $48M
4.8%
TRIM
EQIX $44M
4.3%
TRIM
NTST $42M
4.2%
NEW
CURB $42M
4.2%
ADD
CUZ $40M
3.9%
NEW
BXMT $38M
3.8%
NEW
CBRE $36M
3.6%
ADD
REG $36M
3.5%
TRIM
H $35M
3.5%
NEW
SBAC $34M
3.4%
TRIM
OUT $34M
3.4%
TRIM
PRSU $33M
3.3%
TRIM
LINE $32M
3.1%
TRIM

QoQ vs previous quarter's share count · NEW = new position · ADD/TRIM = ±2% shares · HOLD = unchanged.

Listed as facts. See the verdict above before treating this as signal.

New positions in 2026 Q1

Method & Limitations

Method: a "new position" = held this quarter, absent last quarter (options excluded; stocks with <50 prior holders excluded to filter spin-off artifacts). Entry 47 days after quarter-end — the first day the public could act on the filing. Benchmark = equal-weighted universe of all 13F-held stocks. Limitations: quarterly snapshots can't see intra-quarter trades; survivorship bias — funds that shut down are absent, which flatters the sample. Statistics, not advice.